ContraVir begins dosing in Phase lla trial of CMX157 comparing Viread to treat HBV

US-based biopharmaceutical company ContraVir Pharmaceuticals has initiated dosing patients in its head-to-head Phase lla trial comparing its CMX157 to tenofovir DF (TDF), marketed by Gilead Sciences as Viread to treat chronic hepatitis B (HBV).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news